Lilly and BI, following their SGLT2 rivals, plot kidney disease study for Jardiance
admin 12th June 2017 Uncategorised 0Eli Lilly and Boehringer Ingelheim have reason to believe their SGLT2 inhibitor, Jardiance, may be able to improve outcomes for chronic kidney disease patients—so they’re putting the med to the test.
More: Lilly and BI, following their SGLT2 rivals, plot kidney disease study for Jardiance
Source: fierce